[1]
|
Stapleton, F., Alves, M., Bunya, V.Y., et al. (2017) TFOS DEWS II Epidemiology Report. The Ocular Surface, 15, 334-365. https://doi.org/10.1016/j.jtos.2017.05.003
|
[2]
|
Zhang, Y., Chen, H. and Wu, X. (2012) Prevalence and Risk Factors Associated with Dry Eye Syndrome among Senior High School Students in a County of Shandong Province, China. Ophthalmic Epidemiology, 19, 226-230.
https://doi.org/10.3109/09286586.2012.670742
|
[3]
|
亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表与干眼学组. 中国干眼专家共识: 定义和分类(2020年) [J]. 中华眼科杂志, 2020, 56(6): 418-422.
|
[4]
|
Bron, A.J., de Paiva, C.S., Chauhan, S.K., et al. (2017) TFOS DEWS II Pathophysiology Report. The Ocular Surface, 15, 438-510. https://doi.org/10.1016/j.jtos.2017.05.011
|
[5]
|
De Paiva, C.S., et al. (2019) Topical Cyclosporine A Therapy for Dry Eye Syndrome. Cochrane Database of Systematic Reviews, 3, 78-92. https://doi.org/10.1002/14651858.CD010051.pub2
|
[6]
|
Small, D.S., Acheampong, A., Reis, B., et al. (2002) Blood Concentrations of Cyclosporin A during Long-Term Treatment with Cyclosporin A Ophthalmic Emulsions in Patients with Moderate to Severe Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics, 18, 411-418. https://doi.org/10.1089/10807680260362696
|
[7]
|
Sall, K., Stevenson, O.D., Mundorf, T.K., et al. (2000) Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease. Ophthalmology, 107, 631-639.
https://doi.org/10.1016/S0161-6420(99)00176-1
|
[8]
|
杨怡然, 胡皎月, 刘祖国. 环孢素A在干眼治疗中的价值及应用前景[J]. 中华跟科杂志, 2020, 56(10): 787-795.
|
[9]
|
田小辉, 胡鹿梅, 易湘龙, 等. 0.05%环孢素A治疗干眼有效性和安全性Meta分析[J]. 国际眼科杂志, 2023, 23(2): 248-255.
|
[10]
|
Chen, M., Gong, L., Sun, X., et al. (2010) A Comparison of Cyclosporine 0.05% Ophthalmic Emulsion versus Vehicle in Chinese Patients with Moderate to Severe Dry Eye Disease: An Eight-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Trial. Journal of Ocular Pharmacology and Therapeutics, 26, 361-366.
https://doi.org/10.1089/jop.2009.0145
|
[11]
|
Kilic, S. and Kulualp, K. (2016) Efficacy of Several Therapeutic Agents in a Murine Model of Dry Eye Syndrome. Comparative Medicine, 66, 112-118.
|
[12]
|
Gao, J., Schwalb, T.A., Addeo, J.V., et al. (1998) The Role of Apoptosis in the Pathogenesis of Canine Keratoconjunctivitis Sicca: The Effect of Topical Cyclosporin A Therapy. Cornea, 17, 654.
https://doi.org/10.1097/00003226-199811000-00014
|
[13]
|
Moore, C.P., McHugh, J.B., Thorne, J.G., et al. (2001) Effect of Cyclosporine on Conjunctival Mucin in a Canine Keratoconjunctivitis Sicca Model. Investigative Ophthalmology & Visual Science, 42, 653-659.
|
[14]
|
Wang, Y., Ogawa, Y., Dogru, M., et al. (2008) Ocular Surface and Tear Functions after Topical Cyclosporine Treatment in Dry Eye Patients with Chronic Graft-Versus-Host Disease. Bone Marrow Transplantation, 41, 293-302.
https://doi.org/10.1038/sj.bmt.1705900
|
[15]
|
Chang, H.P., Hyung, K.L., Mee, K.K., et al. (2019) Comparison of 0.05% Cyclosporine and 3% Diquafosol Solution for Dry Eye Patients: A Randomized, Blinded, Multicenter Clinical Trial. BMC Ophthalmology, 19, Article No. 131.
|
[16]
|
沈滢滢, 管怀进, 王立新, 沈晓瑛. 玻璃酸钠滴眼液联合兹润环孢素滴眼液对白内障术后中重度干眼症的疗效分析[J]. 海军医学杂志, 2022, 43(9): 978-982.
|
[17]
|
Wan, K.H., et al. (2015) Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta Analysis. The Ocular Surface, 13, 213-225.
https://doi.org/10.1016/j.jtos.2014.12.006
|